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Abstract
Objective In this study, we develop and apply a high-throughput screening pro-
tocol to investigate the activity of non-ionic surfactants, with a broad range of
hydrophilic–lipophilic balance values, against ABCB1-mediated efflux transport
and ABCC2-mediated efflux transport.
Methods Caco-2 cells were grown for 7 days in 96-well plates, then washed and
incubated with the test materials for 2 h in the presence of 2.5 lM of either rho-
damine 123 (R-123) or 5(6)-Carboxy-20,70 dichlorofluorescein diacetate as
probes of ABCB1 and ABCC2, respectively.
Key findings Of the surfactants tested, no activity against ABCC2 was detected
and all surfactants showing efficacy against ABCB1 had a HLB value of 22 or
below. Inhibition of ABCB1 was seen in the order of efficacy to be poloxamer
335 > poloxamer 40 > Crovol A-70 > Myrj S-40 > poloxamer 184 > poloxamer
182 > Etocas 40 > Tween 20 > Etocas 29 > Tween 80 > Acconon C-44 > Span 20.
With regard to this inhibition, the distribution of hydrophilic regions is more
important than the HLB value.
Conclusion This work demonstrates a high-throughput protocol for detecting
materials that can modulate ABCB1-mediated efflux. These surfactants could be
exploited to improve oral delivery of drugs prone to efflux.
Introduction
Pharmaceutical compounds administered orally must pass
a series of barriers to reach systemic circulation. The
intestinal wall, particularly the jejunum, represents the final
obstacle, coinciding with a high concentration in expres-
sion of efflux transporters. These include the major adeno-
sine triphosphate (ATP)-binding cassette (ABC)
transporters most notably ABCB1 (P-gp) and the mul-
tidrug resistance protein (MRP2, ABCC2)[1] which expel a
broad range of drugs back in to the intestinal lumen,
thereby limiting their bioavailability.
While specific inhibitors of ABCB1 and ABCC2 exist,
many act at such low efficacy that unrealistically high clini-
cal concentrations are required to have an impact in vivo.
Furthermore, many of these inhibitors have their own
undesirable pharmacology. There are numerous reported
examples of excipients (many of which are surfactants) that
can inhibit efflux transporters. Indeed, the effects of
surfactants on efflux-mediated transport first appeared in
the literature with regard to the reversal of multiple drug
resistance, the phenomenon by which solid tumour cells
become refractory in nature by the upregulation the MDR1
gene encoding P-glycoprotein’.[2] This was demonstrated
when the polyethyloxlated castor oils Cremophor EL sensi-
tised the MDR cell lines R100 and K562 to the chemothera-
peutic drug daunorubicin.[3] Since then, a number of
surfactants have been shown to be inhibitors of ABCB1-
mediated transport, including Pluronic P85,[4] D-a-toco-
pheryl polyethylene glycol succinate (TPGS)[5] and Tween
20, Tween 80, Myrj 52 and Brij 30.[6]
In contrast, the impact of surfactants on ABCC2-
mediated transport is less well studied. Cremophor EL,
Cremophor RH 40, Tween 80 and Vitamin E TPGS 1000
have been shown to decrease ABCC2-mediated transport
of anion calcein on MDCKII-ABCC2 cells.[7] In another
study, SF9 membrane vesicles overexpressing ABCC2 were
used to show that Cremophor EL, Cremophor RH 40,
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Pluronic F127 (poloxamer 407), Pluronic F68 (poloxamer
188) and Capmul MCM were able to inhibit MRP2-
mediated transport of scutellarin.[8] A subsequent study by
the authors found that the inhibition of ABCC2 by the
polyethoxylated castor oils was concentration-depen-
dent.[9] However, the distinction between excipients which
inhibit ABCB1 and those which inhibit ABCC2 remains
unclear.
To investigate the potential of surfactants to interact with
these transporters, we have used polarised and differenti-
ated adenocarcinoma (Caco-2) cells. Caco-2 cells are highly
regarded as the in-vitro ‘gold standard’ model for the small
intestine, expressing microvilli and enzymatic components
resembling those of the intestinal epithelium.[10] The cell
line is well characterised and has long been established as a
platform to study ABCB1-mediated transport. More
recently, the Caco-2 cell line has also become a platform for
the study of ABCC2-mediated transport.[11] There are a
variety of in-vitro models that can be employed for screen-
ing ABCC2 activity using Caco-2 cells, with cells grown on
permeable inserts, such as the widely used Transwell
model system, being commonly used as a model for intesti-
nal drug absorption. Although a powerful screening tool,
the Transwell model suffers from slow growth rates that
limit throughput. As such, we have adopted a novel assay
using the Caco-2 platform grown in 96-well plates to
achieve high-throughput screening (HTS) to assess the
intracellular uptake of the fluorescent dye rhodamine 123
(R-123) as a high-affinity ABCB1 probe substrate dye and 5
(6)-carboxy-20,70-dichlorofluorescein as the high-affinity
ABCC2 probe substrate. This HTS protocol offers a num-
ber of advantages over the Transwell model including
reduced growth time, fast processing time, low unit cost, in
a multipurpose platform that can easily be used for fluores-
cent probe uptake as well as cytotoxicity and morphological
studies without modification. In this study, we present a
kinetic evaluation on the impact of surfactants on ABCB1-
mediated transport and ABCC2-mediated transport using
the Caco-2 cell line in this novel high-throughput system,
with the aim of modelling such materials as drug–drug
interactions.
Materials and Methods
Materials
Caco-2 cells (CACO-2; ECACC 09042001) (Public Health
England, Porton Down, Salisbury, UK) were purchased
from Public Health England and used at passage numbers
49-55. L-glutamine, fetal calf serum (FBS), Dulbecco’s
modified Eagle’s medium (DMEM) and non-essential
amino acids (NEAA) were purchased from BioSera (East
Sussex, UK). Ciclosporin (CsA), verapamil (VER),
indometacin (IND), probenecid (PRO), rhodamine 123
(R-123), 5(6)-Carboxy-20,70-dichlorofluorescein diacetate
(CDFDA), MTT, poloxamer 407, Tween 80 and Tween
20 and 0.5% trypsin-EDTA were purchased from Sigma-
Aldrich (Dorset, UK). Capmul MCM, Capmul MCM
C8-2, Capmul PG-12, Capmul PG-8, Acconon C-44
and AccononMC-8 were a kind gift from ABITECH Cor-
poration (Columbus, USA). Poloxamer 182, SpanTM 20,
ArlatoneTM TV, CrovolTM A70, EtocasTM 29, BrijTM S-10,
poloxamer 184, EtocasTM 40, BrijTM CS-12, NatraGemTM
S140, CetomacrogolTM 1000, MyrjTM S40, poloxamer 335,
MyrjTM S100, poloxamer 407 and poloxamer 188 were gifts
from Croda (Goole, UK).
Stock solutions
Stock solutions of excipients were made in fresh Krebs–
Henseleit (KH) buffer (118 mM NaCl, 4.7 mM KCl, 1.2 mM
MgSO4, 1.25 mM CaCl2, 1.2 mM KH2PO4, 25 mM NaHCO3,
11 mM glucose) to a final concentration of 10% (w/v). Fluo-
rescent probes were prepared to 20 lM in DMSO and stored
at 80°C until use. Experimental use of DMSO never
exceeded 0.0125% (v/v), which was not considered to have a
significant impact on the study.
Cytotoxicity and inhibitor activity testing of
excipients
Cytotoxicity and cellular accumulation of tracer dye studies
were studied in Caco-2 cell. Cells were seeded in clear 96-
well plates to a density of 4 9 104 cells per well and grown
for 5–7 days. Cells were grown at 37°C in 5% CO2 with
90% relative humidity in DMEM supplemented with 20%
fetal bovine serum (FBS) for seeding media or 10% FBS for
growth media, 1% non-essential amino acids (NEAA) and
2 mM L-glutamine and in the absence of antibiotics. Media
was renewed every 48 h. Confluence was confirmed using
light microscopy.
To determine an appropriate non-toxic concentration
range to use for testing of the excipients, mitochondrial
activity was measured by the reduction in MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide;
thiazolyl blue) to the insoluble product formazan. Culture
media of confluent 96-well plates was exchanged for
200 ll test solution containing increasing concentrations
of the excipient or drug solutions and incubated for 4 h to
encompass an incubation period longer than operational
exposure time of the cells during assay conditions. The
wells were then emptied and refilled using 100 ll of
0.5 mg/ml MTT and incubated for 3 h. The formazan was
then dissolved using 100 ll of 0.1 N HCl in isopropanol
and absorbance then read at 570 nm. Non-treated control
wells were set to 100% viability.
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To assess inhibitor activity of excipients against ABCB1
and ABCC2, the cellular accumulation of tracer dyes was
employed; dye rhodamine 123 (R-123) was used as a high-
affinity ABCB1 probe substrate and 5(6)-carboxy-20,70-
dichlorofluorescein (CDFDA) as the high-affinity ABCC2
probe substrate. As with the MTT assay, Caco-2 cells seeded
to a density of 4 9 104 cells per well and grown for 5–7 days
were employed. To test inhibitor activity, the monolayers
were washed twice using KH (pH 7.4) and left to equilibrate
for up to 30 min. The wells were then refilled using 200 ll
KH buffer containing the excipient of study over a logarith-
mic concentration range. Following 30 min pre-incubation
with the selected excipient or inhibitor, the wells were emp-
tied and refilled with the same concentrations of excipient or
inhibitors mixed with 2.5 lM of either R-123 or CDFDA.
This step was necessary in order to negate the influence of
excipient viscosity acting to prevent dye ingress. Following
2 h incubation with the transporter probes (37°C in the
dark), the cells were washed three times using ice-cold water
and snap-frozen at 80°C for 5 min or overnight. Cells were
then lysed in double distilled water under refrigeration and
the lysate was transferred to black 96-well plates for fluores-
cence reading (ex 485 nm, em 535 nm).
Calculation of kinetic parameters
To quantify the biological effects of excipients, the half
maximal inhibitory concentration (IC50) values were deter-
mined using GraphPad Prism (Version 6.0, GraphPad Soft-
ware, Inc., San Diego, CA, USA) and represent the
concentration of the tested compound capable of reducing
transporter activity by 50%. Data were normalised against
control cells that were incubated with the appropriate tra-
cer dye but in the absence of an inhibitor, which were set to
100% efflux activity. These IC50 values were then used for
direct comparison to known inhibitors of efflux transporters.
Statistical analysis
All data sets were assessed for significance using analysis of
variance (ANOVA) with a predetermined alpha value of 0.05
using GraphPad Prism (version 6.0) with Dunnett’s multiple
comparison post-test for one-way and two-way ANOVA. In
all figures, the error bars depict standard deviation.
Results and Discussion
Simple and rapid measurement of inhibitor
activity of the ABCB1-mediated transport
and ABCC2-mediated transport
To establish the functional activity of the transporters,
recognised inhibitors of the efflux transporters were tested
in conjunction with the fluorescent probes. Rhodamine 123
(R-123) and 5(6)-Carboxy-20,70-dichlorofluorescein diac-
etate (CDFDA) were used as a high-affinity ABCB1 and
ABCC2 probe substrates, respectively. At low concentra-
tions, the uptake of R-123 has been shown to be a saturable
process that can be inhibited by the organic anion-trans-
port (Oat)1a4 substrates digoxin, quinine, among others,
in the rat model.[12] At higher concentrations, the uptake
of R-123 is by passive diffusion. As an amphiphilic mole-
cule, R-123 is able to traverse the lipid bilayer by inversions
known as ‘flip flop’ events. R-123 excluded by P-gp is free
to continuously re-enter the cell via a process by which the
hydrophobic elements of the compound initially bind to
the acidic head groups of the phospholipids. The efflux of
R-123 by P-gp is mediated by pairs of the probe binding
simultaneously to the protein.[13] Although MRP1 has been
suggested to have a role in R-123 transport,[14] expression
of this efflux transporter is low on the Caco-2 cell line,[15]
and hence specificity of the probe to P-gp. Only mutated
BCRP is capable or transporting R-123 while the wild-type
BCRP cannot.[16]
The results shown in Figure 1 demonstrate that the inhi-
bitors of both ABCB1 (VER and CsA) and ABCC2 (IND
and PBD) follow a dose-dependent response (non-linear
regression curves), allowing IC50 values to 95% confidence
to be calculated. The ABCB1 inhibitors VER and CsA give
IC50 values of 4.08 and 1.16 lM, respectively, with the
ABCC2 inhibitors IND and PBD giving IC50 values of 38.08
and 68.08 lM, respectively (Figure 1). Compared to estab-
lished literature (Table 1), the derived IC50 data for the
ABCB1 inhibitors align well with the published range. For
the inhibitors of ABCC2, the derived IC50 value for IND
also aligns well with published literature, although the
derived value for PBD is an order of magnitude lower than
the published values (Table 1). However, comparative liter-
ature IC50 values for IND and PBD as inhibitors of
ABCC2-mediated efflux are limited, despite their preva-
lence in the literature as common modulators of this trans-
porter. In this respect, the study by Heridi-Szabo et al. was
used to derive two further IC50 values from the Ki values
given.[17]. These Ki values were converted to IC50 values
using the Cheng–Prusoff equation[18] shown in Equation 1,
Ki ¼
IC50
1þ ½S
Km
ð1Þ
where Ki is the inhibitor affinity, the IC50 is the concen-
tration of inhibitor that inhibits 50% of the transport, [S]
is the concentration of the substrate and Km is the sub-
strate affinity.
From the published values collected in Table 1,[17,19–28]
it is apparent that the type of probe and inhibitor combina-
tion used has a notable impact: Rautio et al. used the Caco-
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2 platform in the Transwell format and evaluated the IC50
values of VER using multiple probe substrates.[17] The inhi-
bition IC50 value of VER was found to be below 11 lM
when digoxin and prazosin were used as probe substrates,
between 17 and 34 lM when colchicine and vinblastine
were used as probe substrates, and 60.9 lM when calcein-
AM was used as a probe substrate (Rautio et al., 2006). As
P-gp has known multiple binding sites,[27,28] Rautio et al.
attributed the broad range of inhibition IC50 values to the
different inhibitors exerting their effects on different bind-
ing sites within the transporter.[19] Taken together, the data
present in Figure 1 and Table 1 confirm the functionality
of the ABCB1 and ABCC2 transporter systems on the cell
line by using the combination of specific fluorescent probes
with established inhibitors, subsequently confirming that
the high-throughput 96-well method can be used to mea-
sure inhibitor activity of the ABCB1-mediated transport
and ABCC2-mediated transport.
The effects of surfactants on ABCB1-mediated
efflux and ABCC2-mediated efflux
To examine the underlying structural relationship between
surfactants and efflux inhibition, a broad range of com-
pounds encompassing different HLB values, molecular
weights and structural composition were screened
(Table 2). In general, surfactants have a high propensity to
interact with a lipid bilayer, and in doing can eventually
breach the cell membrane and cause loss of cellular viabil-
ity. As such, all surfactants were tested using the MTT assay
to confirm an appropriate concentration range for further
testing (Figure S1).
Of the 24 surfactants tested, 12 yielded data from which
IC50 values could be determined for ABCB1 inhibition with
over 95% confidence (Figure 2) with the remaining excipi-
ents correlating with linear regression and therefore show-
ing no efflux activity (Table 2). Across the surfactants
tested, only activity against the ABCB1 was detected and
these are shown in Figure 2. Against ABCB1, the excipients
are rank ordered: poloxamer 335, poloxamer 407, Crovol
A-70, Myrj S-40, poloxamer 184, poloxamer 182, Etocas 40,
Tween 20, Etocas 29, Tween 80, Acconon C-44 and Span
20. Of all the excipients, Span gave by far the highest IC50
(7.7 mM; Figure 2a, Table 2). Excluding Span 20, the
remaining excipients had IC50 values of 26.5 lM or below
(Table 2). The excipients with the lowest values, poloxam-
ers 335 and 407, showed IC50 values of 0.63 and 0.71 lM
(Figure 2k and Figure 2l), exceeding that of VER (4.08 lM)
and CsA (1.16 lM) (Figure 1a).
Despite the inherent biological effects of excipients being
well established, supporting kinetic data in the literature
are difficult to find. Tween 80 has been shown to have an
IC50 of 152 lM for inhibition against P-gp using MDR1
overexpressing mouse lymphocytes (P388/mdr) using R-
123 as a substrate.[29] The result of the present study
(12.67 lM; Table 2) is much lower than the previously
reported value and may be attributed to the low membrane
partitioning of P388/mdr cells by Tween 80 which could be
cell type specific. As in our study, Bogman et al. (2003)
raised no significant modulation in the presence of polox-
amer 188 to either ABCB1 or ABCC2.
The mechanism of action of these materials against
ABCB1 is most likely a multifaceted process involving,
among others, ATP depletion by the inhibition of
ATPase[30,31] and/or membrane fluidisation.[6,32] Mem-
brane fluidisation is a fundamental factor in efflux inhibi-
tion due to the sensitivity of ABC transporters to their
microenvironment,[33] in particular P-gp ATPase activity
(Regev et al., 1999). Using porcine kidney epithelial cells
overexpressing P-gp, MRP1 and MRP2, a similar study has
examined Pluronic P85, similar in HLB to poloxamers 184
and 335 used in our study, as an efflux inhibitor.[31] The
degree of ATPase inhibition was observed in the order
MRP1 < MRP2  P-gp, attributed to conformation
changes of the transporter via membrane fluidisation and/
or steric hindrance of drug-binding sites by P85 side chains.
Batrakova et al.[31] suggest that MRP structures may be
more robust and resilient to alterations in fluidisation and
Figure 1 The IC50 curves of inhibitors of efflux proteins, showing
activity against (a) ABCB1 and (b) ABCC2. Caco-2 cells were grown
for 5–7 days on 96-well plates before experimentation. Data pre-
sented as each of a minimum of four replicates from 2.5 lM initial
extracellular concentration of either R-123 or CDFDA as probes of
ABCB1 and ABCC2 activity, respectively.
© 2019 The Authors. Journal of Pharmacy and Pharmacology published by John Wiley & Sons Ltd
on behalf of Royal Pharmaceutical Society, ** (2019), pp. **–**
4
Surfactants influencing drug efflux John Pollard et al.
also that the differences in the overall structures between
P-gp and the MRP isoforms may also play a significant role
by having a binding site which is inaccessible to the long
side chains of the poloxamers.[31] Evers et al. could not find
any correlation between P-gp and MRP inhibition using
Pluronic L61 on MDCKII transfected cell lines.[34] This
may explain why the excipients tested in this study yielded
insufficient inhibition data to give an IC50 value.
When considering the impact of the surfactant structural
attributes, it has previously been noted that the inhibitory
effects of poloxamers against ABCB1 are heavily dependent
upon the HLB of the molecules.[31] In this comprehensive
study, the block copolymers with intermediate propylene
oxide blocks (30–60 units) with HLB values below 20 gave
the optimum inhibition against P-gp in bovine brain
microvessel endothelial cells (BBMECs) by increasing
microviscosity of the lipid membrane and P-gp ATPase
inhibition.[31] Indeed, our findings are in agreement. Of the
five poloxamers tested, only P188 showed no pharmacolog-
ical activity against ABCB1 and was more hydrophilic than
the other poloxamers with a HLB of 29. Yet, closer exami-
nation of Table 2 reveals substantial gaps in the list that
cannot be explained using HLB alone.
Of the materials tested, the lowest molecular weight sur-
factant used is Span 20, which has a comparatively high
IC50 value. Tween 20, with a molecular weight of 1128 Da,
has an IC50 value of 9.7 lM, yet has a very similar molecular
weight to Cetomacrogol 1000 (1122 Da) which had no
effect on ABCB1-mediated efflux (Table 2). For these
materials, the separating factor appears to be the structural
geometry. Tweens have central ring structure from which
PEGylated moieties emanate, divided over three branches.
For Cetomacrogol, the molecule is essentially split in two
distinct regions, the hydrophobic part and the hydrophilic
part in a linear fashion. As membrane interaction and sub-
sequent fluidisation are the generally accepted mechanism
of action, it can be expected that polarised linear chains
represent a larger degree of steric hindrance during lipid
partitioning compared to the compact geometry of Tween
20, through which membrane interactions can pivot
around the hydrophobic ring system. Closely related to
Cetomacrogol 1000, Brij CS-12 and Brij S-10 suffer the
same fate. Myrj S-40 is also a linear chain, but appears to
be able to interact with the membrane, and therefore inhi-
bit, because of its more compact geometry with PEG 40
forming the hydrophilic element. In contrast, Myrj S-100
has no biological effect, most likely attributed to the exten-
sion of the linear chain by PEG 100 as the hydrophilic seg-
ment. Interestingly, Arlatone TV has no inhibitory effect,
yet possesses six branches structure emanating from a sor-
bitol backbone. In this case, the distribution of the PEGyla-
tion appears inadequate (an average of 6.6 repeat units per
branch) to counter the bulk of the molecule. Of all of the
excipients screened, surfactants with intermediate HLB val-
ues that were small and linear or larger and branched
showed high efficacy. It is of interest to note that this study
Table 1 Literature IC50 values of the inhibitors against those obtained from Caco-2 cells grown for 5–7 days on 96-well plates
Drug Structure
Transporter
action Reported IC50 (lM)
Mean
determined
value (lM)
Determined
upper
value (lM)
Determined
lower
value (lM)
Verapamil ABCB1/P-gp 1.18–60.9 Rautio et al. (2006)a 4.08 7.44 2.36
4.2 Wang et al. (2001)b
6.5 Perloff et al. (2002)c
Ciclosporin ABCB1/P-gp 0.5 Tamai and Safa (1991)d 1.16 1.936 0.72
1.4 Wang et al. (2001)b
0.74–2.22 Rautio et al. (2006)a
Indometacin ABCC2/MRP2 25 Colombo et al. (2012)e 38.99 41.4 36.31
46 El-Sheikh et al. (2007)e
75.1 Dahan and Amidon (2010)c
99 Heredi-Szabo et al. (2008)e
Probenecid ABCC2/MRP2 130 Colombo et al. (2012)e 68.08 77.27 60
812 Heredi-Szabo et al. (2008)e
814.8 F€orster et al. (2008)f
Data of determined IC50 values show the outcome of the kinetic modelling using GraphPad prism presented in Figure 1 extrapolated for 50%
transporter inhibition using the sigmoidal curve. aMDCKII-MDR1; bMDR1-NIH3T3-G185; cCaco-2; dVincristine-resistant Chinese hamster lung cells;
eMRP2 membrane vesicles; fMDCK-ABCC2.
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puts a number of IC50 values for the excipients within the
micromolar range and Crovol A70, poloxamer 335 and
poloxamer 407 have efficacy that exceeds verapamil, while
P335 and P407 exceed that of ciclosporin.
This study demonstrates that surfactants such as polox-
amers and Tweens are able to modulate efflux-mediated
transport. Due to the ubiquitous usage of many of these
materials in oral dosage formulations, coupled with the sub-
stantial barrier shown by efflux transporters to many drugs,
it is expected that the work described herein has widespread
pharmacokinetic implications in vivo. Among others, polox-
amers 407, Tween 20, Tween 80 and PEG 40 hydrogenated
castor oil (analogous to Etocas 40 used in the present study)
are widely used in oral formulations as solublising agents,
coatings and constituents of tablets. Both Gengraf and
KALETRA oral solutions contain PEG 40 hydrogenated
castor oil, one of the excipient inhibitors identified in the
present study. Gengraf is a formulation of ciclosporin, a
known inhibitor of P-gp (Tamai and Safa, 1991) and also a
substrate.[35] KALETRA is an oral solution formulation of
both lopinavir and ritonavir. Lopinavir has been shown to
be an ABCB1 substrate in vitro[36–38] and also substrate of
ABCC2.[36] Although ritonavir is an inhibitor of both
ABCB1 and ABCC2,[39,40] this formulation also contains
PEG 40 hydrogenated castor oil. Furthermore, KALETRA
200 mg tablets contain sorbitan monolaurate (Span 20) in
addition to polysorbate 80 (Tween 80) in the coating. One
of the most potent inhibitors found in the present study,
poloxamer 407, is found in many formulations including
ISENTRESS 400 mg film-coated tablets, containing ralte-
gravir. This drug is an ABCB1 substrate in both CD4+ T
cells[41,42] as well as human intestinal cells (Caco-2).[41]
To fully realise these properties, the excipients and the
active compound must together reach the absorbing
membrane, the intestinal epithelium. To achieve this,
they must pass through the stomach. In a study of 12
volunteers, it was found that the stomach volume in the
fasted state is as low as 13–72 ml.[37] With a medium-
sized 500 mg tablet taken with 250 ml of water, the
materials with the lowest IC50 values in our data set, the
poloxamers 335 and 407, would only need to be present
at 1.3 and 2.8 mg, respectively, if taken on an empty
stomach with 72 ml of fluid present. Even in the fed
state, where a stomach can reach volumes of 534–
859 ml,[37] these excipients would need to be present,
theoretically, at 3.5 and 7.6 mg for poloxamers 335 and
407, respectively, for the higher stomach volume, or
1.5% (w/w) and 0.7% (w/w) of a medium-sized 500 mg
tablet, respectively. As such, the data obtained in this
study offer a selection of materials that can be
Table 2 Physical properties and IC50 values against ABCB1 of the tested excipients
Excipient
Physical properties IC50 (lM)
HLBa MW State Average Upper Lower
Capmul PG-8 Propylene glycol monocaprylate 4.5 246b Liquid – – –
Capmul MCM Medium chain monoglycerides and diglycerides 5.5 218b Liquid – – –
Capmul MCM C8 Glyceryl monocaprylate 5.5 202b Liquid – – –
Capmul PG-12 Propylene glycol monolaurate 5.5 258b Liquid – – –
Poloxamer 182 Poly(ethylene) Poly(propylene) glycol 7.0 2500a Liquid 8.57 10.62 7.35
Span 20 Sorbitan monolaurate 8.6 346a Liquid 7725.45 9793.18 6250.69
Arlatone TV PEG 40 sorbitan peroleate 9.0 3508b Liquid – – –
Crovol A-70 PEG 60 almond glyceride 10.0 3251b Liquid 2.56 3.51 1.92
Etocas 29 PEG 29 castor oil 11.7 2202b Liquid 12.00 17.87 8.84
Brij S-10 PEG 10 stearyl ether 12.4 710b Waxy – – –
Poloxamer 184 Poly(ethylene) Poly(propylene) Glycol 13.0 2900a Liquid 7.64 10.11 5.95
Etocas 40 PEG 40 castor oil 13.0 2686b Liquid 9.55 14.45 6.62
Brij CS-12 PEG 12 cetostearyl ether 13.4 770b Waxy – – –
Acconon C-44 Lauroyl macrogolglycerides 13.5 1500a Waxy 26.54 32.88 21.62
NatraGem S140 Polyglyceryl-4 laurate/Sebacate 14.0 664/532b Liquid – – –
Acconon MC8-2 PEG 8 caprylic/Capric glycerides 14.5 350a Waxy – – –
Tween 80 PEG 80 sorbitan monolaurate 15.0 1310a Liquid 12.24 19.89 7.44
Cetomacrogol 1000 PEG 20 cetostearyl ether 15.7 1122b Waxy – – –
Tween 20 PEG 20 sorbitan monolaurate 16.7 1128a Liquid 9.65 12.76 7.41
Myrj S-40 PEG 40 stearate 16.7 2044b Solid 6.13 8.84 4.62
Poloxamer 335 Poly(ethylene) Poly(propylene) glycol 18.0 6500a Solid 0.63 0.75 0.53
Myrj S-100 PEG 100 stearate 18.8 4684b Solid – – –
Poloxamer 407 Poly(ethylene) Poly(propylene) glycol 22.0 12 500a Solid 0.71 0.77 0.70
Poloxamer 188 Poly(ethylene) Poly(propylene) glycol 29.0 8400a Solid – – –
Molecular weight values were either obtained from the manufacturer or estimated from the structures, as given in the parentheses below. All
other values were determined experimentally. aDetermined by manufacturer. bEstimated from molecular weight.
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(a) (b)
(c) (d)
(e) (f)
(g) (h)
(i) (j)
(k) (l)
Figure 2 Percentage inhibition curves of various surfactants against ABCB1 showing (a) Poloxamer 182, (b) Span 20, (c) Crovol A70, (d) Etocas
29, (e) Poloxamer 184, (f) Etocas 40, (g) Acconon C44, (h) Tween 80, (i) Tween 20, (j) Myrj S40, (k) Poloxamer 407 and (l) Poloxamer 335. Sig-
moidal curves were constructed from four different passage numbers on confluent Caco-2 monolayers grown on 96-well plates for 5–7 days and
are shown pooled from a minimum of four replicates per concentration. Data presented as a function of overall R-123 uptake for ABCB1 with ini-
tial conditions of 2.5 lM extracellular tracer dye per well, with excipient-free control wells set to 100% transporter activity.
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incorporated into oral dosage formulations (potentially
in combination to provide synergistic effects) for poten-
tial efflux inhibition in vivo. Furthermore, this work
provides a high-throughput method for the identification
of a working toolbox for the design and production of
tablets with the potential to enhance delivery of drugs
which are prone to efflux. This 96-well plate format
may also be applicable to a wider range of cell models
given its rapid and low-cost nature.
Conclusion
Within this study, a broad range of excipients were
screened using a new HTS assay for activity against
ABCB1-mediated transport and ABCC2-mediated trans-
port, with a number of inhibitors identified. The results
presented in this study demonstrate the potential impact
that surfactants could have on existing oral formulations.
Moreover, these studies describe a series of excipients that
are able to modulate efflux-mediated transport that could
provide a unique method of increasing the uptake of drugs
that are efflux substrates or provide a method for generic
and innovator companies to achieve bioequivalence.
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Supporting Information
Additional Supporting Information
may be found in the online version of
this article:
Figure S1. The effects of the surfac-
tants on cellular viability using the
MTT toxicology assay, showing A)
Capmul PG-8, B) Capmul MCM, C)
Capmul MCM C8, D) Capmul PG-
12, E) Poloxamer 182, F) Span 20, G)
Arlatone TV, H) Crovol A-70, I) Eto-
cas 29, J) Brij S-10, K) Poloxamer
184, L) Etocas 40, M) Brij CS-12, N)
Acconon C-44, O) NatraGem S140,
P) Acconon MC8-2, Q) Tween 80, R)
Cetomacrogol 1000, S) Tween 20, T)
Myrj S-40, W) Poloxamer 335, X)
Myrj S-100, Y) Poloxamer 407, Z)
Poloxamer 188
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